AD Check 認知測™ uses a breakthrough medical technology that has been clinically validated and recognized by the U.S. Food and Drug Administration (FDA) to accurately detect the levels of a biomarker related to Alzheimer’s Disease (AD) pathology in the blood: phosphorylated Tau217 protein (p-Tau217). This helps assess the risk of Alzheimer’s Disease (AD) pathology and allows for regular monitoring of risk changes as individuals age.

Research further indicates that the testing technology used in AD Check 認知測™ is consistent with the results of traditional positron emission tomography (PET-Aβ, PET-Tau) and cerebrospinal fluid biomarkers (CSF Aβ42/40, and CSF p-Tau181).

AD Check認知測™ accuracy reaches 96%, with a sensitivity of 98.2% and a specificity of 98.6%,test by local accredited laboratory.